Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 7/20 | 0.55 |
| ▸ | EGFR | P00533 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510338 | 0.87 | PDGFRB (0.55) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL12144353 | 0.87 | KDR (0.61) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL31108170 | 0.78 | PDGFRB (0.71) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL1367826 | 0.78 | PDGFRB (0.71) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL1366724 | 0.74 | TUBB3 (0.64) | PDGFRBKDREGFRABCB1TUBB3 | |
| SCHEMBL1368125 | 0.70 | KDR (0.54) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL12510337 | 0.69 | PDGFRB (0.58) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL1366483 | 0.68 | PDGFRB (0.57) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL1367379 | 0.67 | PDGFRB (0.58) | PDGFRBKDREGFRMEN1KMT2A | |
| SCHEMBL15586794 | 0.65 | CSF1R (0.43) | PDGFRBKDREGFRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987283-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-05-10 | — | — | US | disclosed |
| US-9802955-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-08-31 | — | — | US | disclosed |
| US-9556198-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170022217-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-01-26 | — | — | US | disclosed |
| US-9458167-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150252053-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2015-09-10 | — | — | US | disclosed |
| US-20150232477-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2015-08-20 | — | — | US | disclosed |
| US-9056869-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-16 | — | — | US | disclosed |
| US-9045489-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2013-04-18 | — | — | US | disclosed |
| US-8309564-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2011-12-01 | — | — | US | disclosed |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | GANGJEE ALEEM (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | PDGFRB 4281/4885KDR 4107/4885EGFR 3072/4885 |
| US-20150252053-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | PDGFRB 4281/4885KDR 4107/4885EGFR 3072/4885 |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | ABCG2, ABCC1, ABCB1 | PDGFRB 4264/4885KDR 4111/4885EGFR 3276/4885 |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | PDGFRB 4281/4885KDR 4107/4885EGFR 3072/4885 |
| US-20170022217-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | PDGFRB 4281/4885KDR 4107/4885EGFR 3072/4885 |
| US-20150232477-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCC1, ABCG2, TP53 | PDGFRB 4450/4885KDR 4411/4885EGFR 3140/4885 |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | PDGFRB 4281/4885KDR 4107/4885EGFR 3072/4885 |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCC1, ABCG2, TP53 | PDGFRB 4450/4885KDR 4411/4885EGFR 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.